References
- Feldman HA, Goldstein I, Hatzichristou DG, . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151:54–61
- Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84:50–6
- El-sakka AI. Characteristics of erectile dysfunction in Saudi patients. Int J Impot Res 2004; 16:13–20
- Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, . Diabetes mellitus in Saudi Arabia. Saudi Med J 2004; 25:1603–10
- Wild S, Roglic G, Green A, . Global prevalence of diabetes. Diabetes Care 2004; 27:1047–53
- Martin-Morales A, Haro JM, Beardsworth A, . Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the Erectile Dysfunction Observational Study (EDOS). Eur Urol 2007; 51:541–50
- Swindle R, Cameron A, Rosen R. A 15-item short form of the psychological and interpersonal relationship scales. Int J Impot Res 2006; 18:82–8
- Rosen RC, Riley A, Wagner G, . The International Index of Erectile Function (IIEF): a multidimensional scale for the assessment of erectile dysfunction. Urology 1997; 49:822–30
- Dean J, Hackett GI, Gentile V, . Psychosocial Outcomes and Drug Attributes Affecting Treatment Choice in Men Receiving Sildenafil Citrate and Tadalafil for the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Open-Label, Crossover Study. J Sex Med 2006; 3:650–61
- Carson C, Rajfer J, Eardley I, . The efficacy and safety of tadalafil: an update. BJU Int 2004; 93:1276–81
- Fonseca V, Seftel A, Denne J, . Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 2004; 47:1914–23